Debanjana Chatterjee
Stock Analyst at JonesTrading
(4.93)
# 170
Out of 4,407 analysts
231
Total ratings
64%
Success rate
43.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintained: Buy | $95 | $80.79 | +17.59% | 18 | Jun 14, 2026 | |
| EYPT EyePoint | Maintained: Buy | $43 | $13.03 | +230.01% | 24 | Jun 11, 2026 | |
| PHVS Pharvaris | Maintained: Buy | $52 | $30.72 | +69.27% | 13 | Jun 11, 2026 | |
| CLSDQ Clearside Biomedical, Inc. | Rated: Hold | n/a | $0.28515 | - | 12 | May 29, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 | $4.04 | +147.52% | 19 | May 27, 2026 | |
| TBPH Theravance Biopharma | Reiterated: Buy | $18 → $19 | $16.62 | +14.32% | 11 | May 27, 2026 | |
| ARMP Armata Pharmaceuticals | Reiterated: Buy | $20 | $7.58 | +163.85% | 5 | May 27, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $29 | $12.11 | +139.47% | 27 | May 27, 2026 | |
| OPTEY Opthea Limited | Rated: Hold | n/a | $0.0251 | - | 8 | May 22, 2026 | |
| ABSI Absci | Maintained: Buy | $11 | $6.80 | +61.76% | 17 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 → $26 | $6.48 | +301.23% | 15 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $63 | $35.92 | +75.39% | 7 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.64 | +354.55% | 16 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $13 | $5.24 | +148.09% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.64 | +174.73% | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $11.94 | +117.76% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $14.21 | +68.90% | 21 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.56 | +220.51% | 1 | Apr 15, 2026 |
Spyre Therapeutics
Jun 14, 2026
Maintained: Buy
Price Target: $95
Current: $80.79
Upside: +17.59%
EyePoint
Jun 11, 2026
Maintained: Buy
Price Target: $43
Current: $13.03
Upside: +230.01%
Pharvaris
Jun 11, 2026
Maintained: Buy
Price Target: $52
Current: $30.72
Upside: +69.27%
Clearside Biomedical, Inc.
May 29, 2026
Rated: Hold
Price Target: n/a
Current: $0.28515
Upside: -
Opus Genetics
May 27, 2026
Reiterated: Buy
Price Target: $10
Current: $4.04
Upside: +147.52%
Theravance Biopharma
May 27, 2026
Reiterated: Buy
Price Target: $18 → $19
Current: $16.62
Upside: +14.32%
Armata Pharmaceuticals
May 27, 2026
Reiterated: Buy
Price Target: $20
Current: $7.58
Upside: +163.85%
Intellia Therapeutics
May 27, 2026
Reiterated: Buy
Price Target: $29
Current: $12.11
Upside: +139.47%
Opthea Limited
May 22, 2026
Rated: Hold
Price Target: n/a
Current: $0.0251
Upside: -
Absci
May 22, 2026
Maintained: Buy
Price Target: $11
Current: $6.80
Upside: +61.76%
May 14, 2026
Reiterated: Buy
Price Target: $31 → $26
Current: $6.48
Upside: +301.23%
May 13, 2026
Maintained: Buy
Price Target: $63
Current: $35.92
Upside: +75.39%
May 12, 2026
Reiterated: Buy
Price Target: $12
Current: $2.64
Upside: +354.55%
May 12, 2026
Reiterated: Buy
Price Target: $11 → $13
Current: $5.24
Upside: +148.09%
May 8, 2026
Maintained: Buy
Price Target: $10
Current: $3.64
Upside: +174.73%
May 8, 2026
Reiterated: Buy
Price Target: $26
Current: $11.94
Upside: +117.76%
May 6, 2026
Maintained: Buy
Price Target: $24
Current: $14.21
Upside: +68.90%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $5
Current: $1.56
Upside: +220.51%